News Mixed outcomes for pharma in big week for FDA adcomms There was good news for Johnson & Johnson at this week's ODAC meetings, but not for Roche, UroGen, and Pfizer.
Market Access New FDA head says no more pharma on advisory committees The announcement signals a new administration attempting to distance itself from industry, but the actual impact seems small.
Oncology BioNTech’s ASCO 2025 oncology advances: New data on bispecif... At ASCO 2025, BioNTech presented 7 abstracts on four selected pipeline candidates in mesothelioma, lung cancer, prostate cancer, and melanoma.
Market Access The value of a partner, globally and locally A new podcast looks at recent trends related to drug approvals, as well as challenges and opportunities both small and large pharma companies face
